Einsatz der Neuen oralen Antikoagulanzien in HausarztpraxenUse of New Oral Anticoagulants in Primary Care Practices

[1] Wagner HO(2013)Neue S1-Handlungsempfehlungen der deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) Z Allg Med 89 496-499

[2] Liesenfled A(2012)ESC guidelines for the management of atrial fibrillation an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Europace 14 1385-1413

[3] Camm AJ(2014)AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2014 e1-e76

[4] Lip GY(2010)A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 1093-1100

[5] January CT(1996)Van den, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name. A review of literature Eur J Gen Pract 2 65-70

[6] Wann LS(2014)Anticoagulant treatment in German family practices–screening results from a cluster randomized controlled trial BMC Fam Pract 15 170-1414

[7] Alpert JS(2014)A national assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation Circulation 129 1407-618

[8] Pisters R(2013)Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in polish patients receiving acenocoumarol: dosing calculation algorithm Pharmacogenet Genomics 23 611-150

[9] Lane DA(2008)Pharmacogenetic testing of cyp2c9 and vkorc1 alleles for warfarin Genet Med 10 139-334

[10] Nieuwlaat R(2012)Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Lancet 379 322-undefined

[1] Wagner HO(2013)Neue S1-Handlungsempfehlungen der deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) Z Allg Med 89 496-499

[2] Liesenfled A(2012)ESC guidelines for the management of atrial fibrillation an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Europace 14 1385-1413

[3] Camm AJ(2014)AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2014 e1-e76

[4] Lip GY(2010)A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 1093-1100

[5] January CT(1996)Van den, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name. A review of literature Eur J Gen Pract 2 65-70

[6] Wann LS(2014)Anticoagulant treatment in German family practices–screening results from a cluster randomized controlled trial BMC Fam Pract 15 170-1414

[7] Alpert JS(2014)A national assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation Circulation 129 1407-618

[8] Pisters R(2013)Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in polish patients receiving acenocoumarol: dosing calculation algorithm Pharmacogenet Genomics 23 611-150

[9] Lane DA(2008)Pharmacogenetic testing of cyp2c9 and vkorc1 alleles for warfarin Genet Med 10 139-334

[10] Nieuwlaat R(2012)Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Lancet 379 322-undefined